CYP2C19

• This variability in drug response is what pharmacogenomic testing hopes to explain by looking at the genes within your DNA.
• Pharmacogenomics, or PGx, is the study of how genes affect your response to medications.

How do PGx tests work?

• PGx tests look for variations within the genes of your DNA to predict drug response.
• There are commercially available PGx tests that patients can have sent directly to their doorstep with or without the involvement of a health care professional.
• These direct-to-consumer PGx tests collect DNA from either a saliva sample or cheek swab that is then sent to the laboratory.

Limitations of PGx testing

• PGx testing will not be able to predict how you will respond to all medications for several reasons.
• PGx tests can predict how you will respond only to medications associated with the genes it tests for.
• Some drugs are broken down in very complicated pathways entailing multiple proteins and byproducts, and the usefulness of PGx testing for them remains unclear.
• In other words, PGx testing is predictive rather than deterministic.

Risks of PGx testing

• PGx testing carries the risk of not telling the whole story of drug response.
• If variations within the gene are not found, the testing company often assumes the proteins those genes code for function normally.
• Sharing your PGx test results with all the clinicians involved in your care can help prevent medication failure and improve safety.

Benefits of PGx testing

• Direct-to-consumer PGx testing can empower patients to advocate for themselves and be an active participant in their health care by increasing access to and knowledge of their genetic information.
• Patients’ knowledge of their PGx genetic profile has the potential to improve treatment safety.

• Mavacamten also demonstrated improvement across all secondary endpoints, including LVOT obstruction, clinical symptoms, and health status.
• The data presented at ESC 2023 and published in JAMA Cardiology continue to demonstrate robust evidence of mavacamten’s therapeutic benefit.
• As previously reported, safety results in the trial were consistent with previous studies of mavacamten in symptomatic oHCM, and no new safety signals were reported.
• “The EXPLORER-CN trial demonstrates that the well-established therapeutic benefit of this drug also extends to Chinese patients.

• The Facility and the Company's existing cash resources will be directed towards the commercialisation of the Company's Antibiotic Induced Hearing Loss test, Genedrive® MT-RNR1 ID Kit ("AIHL test") and enhancing the Genedrive® platform through the validation and verification of the Company's CYP2C19 test, Genedrive® CYP2C19 ID Kit ("CYP2C19 test") as well as providing additional working capital.
• The company are currently developing a genetic test for CYP2C19 metaboliser status.
• The Genedrive®MT-RNR1 ID Kit, selected as 1 of the 10 EVA pilot projects, is the world's first commercial point-of-care genetic test for emergency care.
• It helps to avoid irreversible lifelong hearing loss in specific infants exposed to aminoglycosides by rapidly detecting the m.1555A>G gene variant that can cause lifelong deafness, allowing for alternative antibiotics to be prescribed.

• At the time of topline analysis, the safety of TALZENNA plus XTANDI were generally consistent with the known safety profile of each medicine.
• Detailed results from TALAPRO-2 will be submitted for presentation at a near-term medical congress.
• In addition to the TALAPRO-2 trial, the combination of TALZENNA plus XTANDI is being investigated in the TALAPRO-3 trial ( NCT04821622 ), a global, randomized, double-blind, placebo-controlled Phase 3 study in men with HRR-deficient mCSPC.
• Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.